BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Hurtado J, Carrellas M, Marcus J, Marchesi JR, McDonald JAK, Gerardin Y, Silverstein M, Pechlivanis A, Barker GF, Miguens Blanco J, Alexander JL, Gallagher KI, Pettee W, Phelps E, Nemes S, Sagi SV, Bohm M, Kassam Z, Fischer M. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Inflamm Bowel Dis 2021;27:1371-8. [PMID: 33155639 DOI: 10.1093/ibd/izaa283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Conrad MA, Kelsen JR. Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease: A Clinician's Dilemma. J Pediatric Infect Dis Soc 2021:piab069. [PMID: 34343321 DOI: 10.1093/jpids/piab069] [Reference Citation Analysis]
2 Dalal RS, Allegretti JR. Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease. Curr Opin Gastroenterol 2021;37:336-43. [PMID: 33654015 DOI: 10.1097/MOG.0000000000000739] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Joachim A, Schwerd T, Hölz H, Sokollik C, Konrad LA, Jordan A, Lanzersdorfer R, Schmidt-Choudhury A, Hünseler C, Adam R. [Fecal Microbiota Transfer (FMT) in Children and Adolescents - Review and statement by the GPGE microbiome working group]. Z Gastroenterol 2022. [PMID: 35533688 DOI: 10.1055/a-1801-0284] [Reference Citation Analysis]
4 Sehgal K, Yadav D, Khanna S. The interplay of Clostridioides difficile infection and inflammatory bowel disease. Therap Adv Gastroenterol 2021;14:17562848211020285. [PMID: 34104215 DOI: 10.1177/17562848211020285] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Ianiro G, Bibbò S, Porcari S, Settanni CR, Giambò F, Curta AR, Quaranta G, Scaldaferri F, Masucci L, Sanguinetti M, Gasbarrini A, Cammarota G. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes 2021;13:1994834. [PMID: 34709989 DOI: 10.1080/19490976.2021.1994834] [Reference Citation Analysis]
6 Lou P, Shen Y, Zhuge A, Lv L, Zhu X, Yuan Y, Yang L, Wang K, Li B, Li L. Dose-Dependent Relationship between Protection of Thioacetamide-Induced Acute Liver Injury and Hyperammonemia and Concentration of Lactobacillus salivarius Li01 in Mice. Microbiol Spectr 2021;9:e0184721. [PMID: 34937168 DOI: 10.1128/spectrum.01847-21] [Reference Citation Analysis]
7 Stojek M, Jabłońska A, Adrych K. The Role of Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease. J Clin Med 2021;10:4055. [PMID: 34575166 DOI: 10.3390/jcm10184055] [Reference Citation Analysis]
8 Gweon TG, Lee YJ, Kim KO, Yim SK, Soh JS, Kim SY, Park JJ, Shin SY, Lee TH, Choi CH, Cho YS, Yong D, Chung JW, Lee KJ, Lee OY, Choi MG, Choi M; Gut Microbiota and Therapy Research Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea. J Neurogastroenterol Motil 2022;28:28-42. [PMID: 34980687 DOI: 10.5056/jnm21221] [Reference Citation Analysis]
9 Li Q, Ding X, Liu Y, Marcella C, Dai M, Zhang T, Bai J, Xiang L, Wen Q, Cui B, Zhang F. Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn's Disease. Front Pharmacol 2021;12:658087. [PMID: 34079458 DOI: 10.3389/fphar.2021.658087] [Reference Citation Analysis]